Rise and shine, everyone, the middle of the week is here. You made it this far, so why not forge ahead, yes? As always, we are doing our best with the help of some cups of stimulation — we are quaffing hazelnut this morning — and invite you to join us. After all, a prescription is not required, so go ahead and indulge. Meanwhile, we have assembled the latest menu of tidbits to get you started on another busy day. Hope all goes well and you conquer the world. Cheers …
Emergent BioSolutions (EBS) agreed to buy Adapt Pharma, which sells Narcan, the only needle-free emergency opioid overdose treatment approved in the U.S., Reuters writes. Emergent said it had “no plans to change” Narcan pricing and would maintain a 40 percent discount available to state and local governments and nonprofits. Narcan, which is often carried by police officers and medical teams, contains naloxone hydrochloride and was approved as a nasal spray in 2015. The U.S. Surgeon General released a public health advisory earlier this year urging more Americans to carry naloxone.
Alcon, the Novartis (NVS) eye-care unit, is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the drug maker maintained the move would not affect plans to spin off the unit next year, according to Reuters. As part of its voluntary withdrawal of the CyPass Micro-Stent, Alcon advised surgeons treating glaucoma patients to stop implanting the stents immediately. Five-year post-surgery data showed patients experienced statistically significant endothelial cell loss compared to the group of patients who underwent cataract surgery alone.
About the Author Reprints
